Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Cadrenal Therapeutics, Inc. (CVKD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
4Distinct source URLs
10High confidence
0.805Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cadrenal Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
EXITHERA-PHARMACEUTICALS-INC
EXITHERA-PHARMACEUTICALS-INC
92%
On September 12, 2025, we entered into an asset purchase agreement (the “eXIthera Purchase Agreement”) with eXIthera Pharmaceuticals, Inc. (“eXIthera”), to acquire its assets
VERALOX
VERALOX
92%
On December 10, 2025, we entered into the Veralox Purchase Agreement pursuant to which Veralox sold to us all, or substantially all, of its right title and interest in the Veralox Assets
EXITHERA
EXITHERA
90%
The Company agreed to pay the eXIthera royalties equal to 2 % of annual net sales of the pharmaceutical products containing any compounds that are subject to the eXIthera APA.
OLD-DOMINION-UNIVERSITY
OLD-DOMINION-UNIVERSITY
90%
The Veralox Assets also include the assignment of an Amended and Restated Exclusive License Agreement by and between Veralox and Old Dominion University, as successor in interest to Eastern Virginia …
WAINWRIGHT
WAINWRIGHT
90%
The Company entered into an engagement agreement with Wainwright, dated August 14, 2025, pursuant to which Wainwright agreed to act as the exclusive placement agent for the Company
HAISCO
HAISCO
80%
The Company agreed to pay eXIthera 50 % of all royalties received by the Company from the Haisco Licensing Agreement following the potential future commercialization of frunexian by Haisco.
we will raise sufficient funds to support the planned Phase 3 trial or that the trial design will be accepted by the FDA. 18 Manufacturing We do not have a manufacturing infrastructure and do not int…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CVKD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CVKD graph: we will raise sufficient funds to…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CVKD graph: s, government agencies and other public and private research organizations that conduct research, seek patent protec…
s, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufactur…
KEY-MANUFACTURING-PARTNERS
KEY-MANUFACTURING-PARTNERS
62%
candidates are manufactured by more than one supplier, the number of suppliers is limited. In the event it is necessary or advisable to acquire drug materials, substances, and products from alternati…
SICHUAN-HAISCO-PHARMACEUTICAL-CO-LTD
SICHUAN-HAISCO-PHARMACEUTICAL-CO-LTD
62%
ther than in a particular research and development project. For an IPR&D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in an alte…
VERALOX-THERAPEUTICS-INC
VERALOX-THERAPEUTICS-INC
62%
e Company to the Seller of eXIthera upon achievement of development milestones in an amount not to exceed $ 15 million. Development Milestones Milestone payment First Patient Dosed in Phase 2 Initiat…
Cadrenal Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CVKD-DEBT
Debt stack $597,068
90%
Market cache reports total debt of $597,068.
CVKD-DEBT-8952
Warrants outstanding: 18571
90%
xbrl warrant detail from xbrl 2025-09-30.
CVKD-DEBT-8953
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
Cadrenal Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cadrenal Therapeutics, Inc..
Cadrenal Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CVKD-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 17 tracked holders.
Cadrenal Therapeutics, Inc. Extended Supply Chain Network
